Immunosuppressant drug monitoring: A routine undertaking?;Immunsuppressiva-Medikamentenspiegelmessung reine Routine?

LaboratoriumsMedizin

Volumn 34, Issue 3, 2010, Pages 117-128

  Seger, Christoph ^a   Vogeser, Michael ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immunoassays; Immunosuppressant drugs; Liquid chromatography tandem mass spectrometry (LC MS MS); Proficiency testing; Tandem mass spectrometry; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

DRUG DETERMINATION; DRUG MONITORING; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; REVIEW; TANDEM MASS SPECTROMETRY;

EID: 77952382050     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2010.027     Document Type: Review

References (80)

1. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002;24:330-50.
2. Sayegh MH, Carpenter CB. Transplantation 50 years later - progress, challenges, and promises. N Engl J Med 2004;351:2761-6.
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29.
4. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: Recent developments. Ther Drug Monit 2006;28:720-5.
5. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation: An overview. Drugs 2008;68:2113-30.
6. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83.
7. Marcen R. Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69:2227-43.
8. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95.
9. http://Eur-lex.europa.eu/LexUriServ/LexUriServ. do?urisCON-SLEG: 1998L0079:20031120:De:Pdf. Abfrage am 17.3.2010.
10. Vogeser M. Liquid chromatography-tandem mass spectrometry application in the clinical laboratory. Clin Chem Lab Med 2003;41:117-26.
11. Vogeser M, Parhofer KG. Liquid chromatography tandem-mass spectrometry (LC-MS/MS)-technique and applications in endocrinology. Exp Clin Endocrinol Diabetes 2007;115:559-70.
12. Vogeser M, Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory - goals for further developments. Clin Biochem 2008;41:649-62.
13. Korecka M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant 2009;14:61-72.
14. Chapman TM, Perry CM. Everolimus. Drugs 2004;64:861-72.
15. Bocchi E, Ahualli L, Amuchastegui M, Boullon F, Cerutti B, Colque R, et al. Recommendations for use of everolimus after heart transplantation: Results from a Latin-American Consensus Meeting. Transplant Proc 2006;38:937-42.
16. Fraser CG, Hyltoft Petersen P, Larsen ML. Setting goals for random analytical error in specific clinical monitoring situations. Clin Chem 1990;36:1625-8.
17. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific? Clin Chem 1999;45:371-81.
18. Schütz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, et al. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC. Clin Chem 1998;44:2158-64.
19. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. ELITE-Symphony study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75.
20. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result. Clin J Am Soc Nephrol 2008;3:S101-16.
21. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit 2009;31:139-52.
22. Yatscoff RW, Boeckx R, Holt DW, Kahan BD, LeGatt DF, Sehgal S, et al. Consensus guidelines for therapeutic drug monitoring of rapamycin: Report of the consensus panel. Ther Drug Monit 1995;17:676-80.
23. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International federation of clinical chemistry/international association of therapeutic drug monitoring and clinical toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit 2002;24:59-67.
24. Schütz E, Shipkova M, Wieland E, Niedmann PD, Armstrong VW, Oellerich M. Evaluation of an immunoassay for mycophenolic acid. Ther Drug Monit 2000;22:141-2.
25. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 1999;31:1135-7.
26. Makela SK, Ellis G. Nonspecificity of a direct 17alpha- hydroxyprogesterone radioimmunoassay kit when used with samples from neonates. Clin Chem 1988;34:2070-5.
27. Perogamvros I, Owen LJ, Newell-Price J, Ray DW, Trainer PJ, Keevil BG. Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: Application in basal and stimulated conditions. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3771-5.
28. Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004;50:621-5. (Pubitemid 38297314)
29. Steimer W, Müller C, Eber B. Digoxin assays: Frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem 2002;48:507-16.
30. Dasgupta A. Herbal supplements and therapeutic drug monitoring: Focus on digoxin immunoassays and interactions with St. John's wort. Ther Drug Monit 2008;30:212-7.
31. Dewitte K, Fierens C, Stöckl D, Thienpont LM. Application of the Bland-Altman plot for interpretation of method-comparison studies: A critical investigation of its practice. Clin Chem 2002;48:799-801.
32. Fingerhut R. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values. Steroids 2009;74:662-5.
33. Petersen PH, de Verdier CH, Groth T, Fraser CG, Blaabjerg O, Horder M. The influence of analytical bias on diagnostic misclassifications. Clin Chim Acta 1997;260:189-206.
34. Siegel RW, Baugher W, Rahn T, Drengler S, Tyner J. Affinity maturation of tacrolimus antibody for improved immunoassay performance. Clin Chem 2008;54:1008-17.
35. Staples MA. Reagents for assays for mycophenolic acid. WO9803876.
36. Staples MA, Haley CJ, Parrish RF, Zmolek WW. Releasing reagents for assays for ligands, and application to determination of mycophenolic acid. WO9803877.
37. Seger C, Tentschert K, Griesmacher A. Evaluating performance limitations of a tacrolimus immunoassay by comparison with a HPLC-MS/MS platform. Ther Drug Monit 2007;29:509.
38. Napoli KL. Is microparticle enzyme-linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant recipients. Ther Drug Monit 2006;28:491-504.
39. Brown NW, Gonde CE, Adams JE, Tredger JM. Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry. Clin Chem 2005;51:586-92.
40. Bouzas L, Ortega FJ, Casado P, Arranz MI, Carcas A, Tutor JC. Effect of the hematocrit and its correction on the relationship between blood tacrolimus concentrations obtained using the microparticle enzyme immunoassay (MEIA) and enzyme multiplied immunoassay technique (EMIT). Clin Lab 2007;53:591-6.
41. Tomita T, Homma M, Hasegawa Y, Kojima H, Ohkohchi N, Hori T, et al. Use of sample hematocrit value to correct blood tacrolimus concentration derived by microparticle enzyme immunoassay. Biol Pharm Bull 2008;31:1250-3.
42. Schmid RW, Lotz J, Schweigert R, Lackner K, Aimo G, Friese J, et al. Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer. Clin Biochem 2009;42:1543-8.
43. Maine GT, Edwards M, Haverstick DM, Sluss P, Young J, Schmidt E, et al. Analytical evaluation of the Abbott ARCHI-TECT cyclosporine assay in comparison to LC/MS/MS and Abbott TDX/FLX. Clin Biochem 2008;41:1274.
44. Maine GT, Wallemacq P, Ait-Youcef H, Berg K, Young J, Schmidt E, et al. Analytical evaluation of the Abbott ARCHI-TECT cyclosporine assay in comparison to LC/MS/MS and Dade Dimension Xpand. Clin Biochem 2008;41:1274-5.
45. Boer K, Brehmer-Streck S, Deufel T, Schmidt D, Kiehntopf M. Automated monitoring of C2 and C0 blood levels of mycophenolic acid and cyclosporine on the Abbott Architect c8000. Clin Biochem 2007;40:1163-7.
46. Siegel RW, Baugher W, Rahn T, Drengler S, Tyner J. Affinity maturation of tacrolimus antibody for improved immunoassay performance. Clin Chem 2008;54:1008-17.
47. Schmid S, Gruber B, Schmid RW. Semi-automated & automated sample preparation for the immunological immunesuppressant monitoring on the Architect analyzer. Ther Drug Monit 2009;51:650.
48. Hermida J, Tutor JC. Falsely increased blood tacrolimus concentrations using the ACMIA assay due to circulating endogenous antibodies in a liver transplant recipient: A tentative approach to obtaining reliable results. Ther Drug Monit 2009;31:269-72.
49. Altinier S, Varagnolo M, Zaninotto M, Boccagni P, Plebani M. Heterophilic antibody interference in a non-endogenous molecule assay: An apparent elevation in the tacrolimus concentration. Clin Chim Acta 2009;402:193-5.
50. Moscato D, Nonnato A, Adamo R, Vancheri M, Caropreso A. Therapeutic monitoring of tacrolimus: Aberrant results by an immunoassay with automated pre-treatment. Clin Chim Acta 2010;411:77-80.
51. Martin BB, Marquet P, Ferrer JM, Puig BC, Bennasar AB, Prieto MR, et al. Rheumatoid factor interference in a tacrolimus immunoassay. Ther Drug Monit 2009;31:743-5.
52. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145-54. (Pubitemid 44314941)
53. Kuypers DR, Meur YL, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5:341-58.
54. Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: Association with clinical outcome. Curr Med Res Opin 2006;22:2355-64.
55. Premaud A, Rousseau A, Le Meur Y, Lachatre G, Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004;26:609-19.
56. Shipkova M, Schütz E, Besenthal I, Fraunberger P, Wieland E. Investigation of the crossreactivity of mycophenolic acid glucuronide metabolites and of mycophenolate mofetil in the Cedia MPA assay. Ther Drug Monit 2010;32:79-85.
57. van Gelder T, Domke I, Engelmayer J, de Fijter H, Kuypers D, Budde K, et al. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. Ther Drug Monit 2009;31:218-23.
58. Brandhorst G, Marquet P, Shaw LM, Liebisch G, Schmitz G, Coffing MJ, et al. Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. Ther Drug Monit 2008;30:428-33.
59. Kebarle P, Verkerk UH. Electrospray: From ions in solution to ions in the gas phase, what we know now. Mass Spectrom Rev 2009;28:898-917.
60. Covey TR, Thomson BA, Schneider BB. Atmospheric pressure ion sources. Mass Spectrom Rev 2009;28:870-97.
61. Vogeser M, Spöhrer U. Pitfall in the high-throughput quantification of whole blood cyclosporin A using liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005;43:400-2.
62. Vogeser M, Zachoval R, Spöhrer U, Jacob K. Potential lack of specificity using electrospray tandem-mass spectrometry for the analysis of mycophenolic acid in serum. Ther Drug Monit 2001;23:722-4.
63. Ceglarek U, Lembcke J, Fiedler GM, Werner M, Witzigmann H, Hauss JP, et al. Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry. Clin Chim Acta 2004;346:181-90.
64. Seger C, Tentschert K, Stöggl W, Griesmacher A, Ramsay SL. A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples. Nat Protoc 2009;4:526-34.
65. Napoli KL. Is microparticle enzyme-linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant recipients. Ther Drug Monit 2006;28:491-504.
66. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.
67. Taylor PJ. Matrix effects: The Achilles heel of quantitative highperformance liquid chromatography-electrospray-tandem mass spectrometry. Clin Biochem 2005;38:328-34.
68. Thienpont LM, Van Uytfanghe K, Blincko S, Ramsay CS, Xie H, Doss RC, et al. State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-tandem mass spectrometry. Clin Chem 2008;54:1290-7.
69. Wang S, Cyronak M, Yang E. Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/MS/MS method for the determination of carvedilol enantiomers in human plasma. J Pharm Biomed Anal 2007;43:701-7.
70. Lindegardh N, Annerberg A, White NJ, Day NP. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 2008;862:227-36.
71. Taylor PJ. Internal standard selection for immunosuppressant drugs measured by high-performance liquid chromatography tandem mass spectrometry. Ther Drug Monit 2007;29:131-2.
72. Taylor PJ, Brown SR, Cooper DP, Salm P, Morris MR, Pillans PI, et al. Evaluation of 3 internal standards for the measurement of cyclosporin by HPLC-mass spectrometry. Clin Chem 2005;51:1890-3.
73. Hoogtanders K, van der Heijden J, Stolk LM, Neef C, Christiaans M, van Hooff J. Internal standard selection for the highperformance liquid chromatography tandem mass spectroscopy assay of everolimus in blood. Ther Drug Monit 2007;29:673-4.
74. Steele BW, Wang E, Soldin SJ, Klee G, Elin RJ, Witte DL. A longitudinal replicate study of immunosuppressive drugs. Arch Pathol Lab Med 2003;127:283-8.
75. Holt D, Moreton M, Laamanen K, Johnston A. A microparticle enzyme immunoassay to measure sirolimus. Transplant Proc 2005;37:182-4.
76. Tietz NW. Accuracy in clinical chemistry - does anybody care? Clin Chem 1994;40:859-61.
77. Müller MM. Implementation of reference systems in laboratory medicine. Clin Chem 2000;46:1907-9.
78. Thienpont LM. Accuracy in clinical chemistry - who will kiss sleeping beauty awake? Clin Chem Lab Med 2008;46:1220-2.
79. Stöckl D, Sluss PM, Thienpont LM. Specifications for trueness and precision of a reference measurement system for serum/plasma 25-hydroxyvitamin D analysis. Clin Chim Acta 2009;408:8-13.
80. Anonymous. Quality Review Investigating the Underestimation of Cyclosporine Levels Preliminary Report (Eastern Health, Canada 2010). http://Www.easternhealth.ca/viewNewsPDF.aspx?ds1&ids61&ps52& nids235. Abfrage am 17.3.2010.